Cubist Systematic Strategies LLC Has $2.50 Million Position in Ginkgo Bioworks Holdings, Inc. $DNA

Key Points

• Cubist Systematic Strategies LLC significantly increased its holdings in Ginkgo Bioworks by 188.9% in Q1, now owning 439,259 shares valued at approximately $2.50 million.
• Ginkgo Bioworks reported a loss of ($1.10) earnings per share for the quarter, exceeding analysts' expectations of ($1.44) and achieving revenue of $49.60 million.
• The stock price of Ginkgo Bioworks has fluctuated between $5.00 and $16.85 over the past year and currently carries an average rating of "Hold" from analysts.

Cubist Systematic Strategies LLC increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 188.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 439,259 shares of the company's stock after buying an additional 287,221 shares during the period. Cubist Systematic Strategies LLC owned 0.76% of Ginkgo Bioworks worth $2,504,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in DNA. Bank of America Corp DE increased its holdings in Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after buying an additional 3,336,964 shares during the last quarter. Erste Asset Management GmbH grew its holdings in Ginkgo Bioworks by 123.2% during the first quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company's stock valued at $9,405,000 after purchasing an additional 910,668 shares during the last quarter. Millennium Management LLC grew its holdings in Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after purchasing an additional 523,571 shares during the last quarter. Forbes J M & Co. LLP grew its holdings in Ginkgo Bioworks by 56.0% during the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after purchasing an additional 392,832 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Ginkgo Bioworks during the first quarter valued at approximately $733,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 4.8%

Shares of DNA stock opened at $11.12 on Friday. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $16.85. The firm's fifty day simple moving average is $12.16 and its 200 day simple moving average is $9.28. The firm has a market capitalization of $658.01 million, a P/E ratio of -1.90 and a beta of 1.50.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. The business had revenue of $49.60 million for the quarter, compared to analyst estimates of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DNA has been the topic of several analyst reports. Cowen reiterated a "buy" rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Wall Street Zen upgraded Ginkgo Bioworks from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Finally, BTIG Research increased their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a report on Monday, August 25th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $9.50.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.